Lawmakers question makers on key Vytorin meeting
WASHINGTON (Reuters) - Two U.S. Democrats said on Friday their investigation had raised questions about how Merck & Co Inc and Schering-Plough Corp documented a key meeting about a controversial study of their Vytorin cholesterol drug.
<p><img src="http://feeds.reuters.com/~a/reuters/businessNews?i=dw5xCe" border="0"></img> (http://feeds.reuters.com/~a/reuters/businessNews?a=dw5xCe)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/businessNews?i=PcjXf9G" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=PcjXf9G) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=5xRnKmg" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=5xRnKmg) <img src="http://feeds.reuters.com/~f/reuters/businessNews?i=aZA4iYg" border="0"></img> (http://feeds.reuters.com/~f/reuters/businessNews?a=aZA4iYg)
</div><img src="http://feeds.reuters.com/~r/reuters/businessNews/~4/268698157" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/businessNews/~3/268698157/idUSN1133394420080412